Obicetrapib - NewAmsterdam Pharma
Alternative Names: AMG 899; DEZ 001; obicetripib; TA-8995Latest Information Update: 14 Aug 2024
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Amgen; Mitsubishi Tanabe Pharma Corporation; NewAmsterdam Pharma
- Class Antidementias; Antihyperlipidaemics; Heterocyclic compounds; Quinolines; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Dyslipidaemias; Hyperlipoproteinaemia type IIa
- Phase II Alzheimer's disease; Hypercholesterolaemia
Most Recent Events
- 09 Aug 2024 NewAmsterdam Pharma plans a phase I Drug-Drug interaction study in Canada (NCT06547359)
- 29 Jul 2024 Efficacy and adverse events data from the phase III BROOKLYN trial in Hyperlipoproteinaemia type IIa release by Menarini (9422266
- 11 Jul 2024 NewAmsterdam Pharma plans a phase II VINCENT trial for Dyslipidemias (Monotherapy, Combination therapy) in August 2024(NCT06496243)